Francisco Javier Ramos

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

Josep Tabernero, Federico Rojo, Emiliano Calvo et al. · Journal of Clinical Oncology · 2008 · 528 citations

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors

Ferry A.L.M. Eskens, Francisco Javier Ramos, Herman Burger et al. · Clinical Cancer Research · 2013 · 246 citations · Full text

A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma

Amitesh Roy, S. R. Park, David Cunningham et al. · Annals of Oncology · 2013 · 121 citations · Full text

Esophageal Cancer, Gastrointestinal Oncology, Gastro-oesophageal Junction Adenocarcinoma +10

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study

Josep Tabernero, Fortunato Ciardiello, Fernando Rivera et al. · Annals of Oncology · 2009 · 90 citations · Full text

Dose-escalation Study, Oncology, Gastrointestinal Oncology +7

Severe Serotonin Syndrome Induced by Mirtazapine Monotherapy

José L. Hernández, Francisco Javier Ramos, Jon Infante et al. · Annals of Pharmacotherapy · 2002 · 55 citations